Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03519386 · ClinicalTrials.gov registry record · Phase 3
Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%
A Phase 3 study of Ocular Hypertension and Glaucoma Open-Angle, sponsored by Glaukos Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 590
- Enrollment target
- 1
- Study location
NCT03519386 is a Phase 3 study of Ocular Hypertension and Glaucoma Open-Angle that has completed, run by Glaukos Corporation. The registered enrollment target is 590 participants, above the 267-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (121% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03519386, a Phase 3 study of Ocular Hypertension and Glaucoma Open-Angle, has completed, sponsored by Glaukos Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 590 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase III study to compare the safety and efficacy of intraocular implants containing travoprost at two different elution rates versus Timolol Maleate Ophthalmic Solution, 0.5% (timolol) in reducing elevated intraocular pressure in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Conditions Studied
Interventions
- COMBINATION_PRODUCT G2-TR intraocular implant containing travoprost
- DRUG Sham surgery + active-comparator eye drops
Study Locations (1)
South Dakota
- Vance Thompson Vision - Sioux Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 590 participants |
| Start Date | 2018-07-26 |
| Est. Completion | 2024-04-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03519386
The ClinicalTrials.gov registry entry for NCT03519386 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 590 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 267-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (121% higher). The listed sponsor is Glaukos Corporation, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 2 interventions - of which G2-TR intraocular implant containing travoprost is the first listed.
NCT03519386 reports 1 study location spanning 1 distinct geographic area - top geographies include South Dakota.
Frequently Asked Questions
What is clinical trial NCT03519386 about?
NCT03519386 is a clinical study titled "Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%". Phase III study to compare the safety and efficacy of intraocular implants containing travoprost at two different elution rates versus Timolol Maleate Ophthalmic Solution, 0.5% (timolol) in reducing elevated intraocular pressure in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT)...
What is the current status of trial NCT03519386?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 590 participants. The study started on 2018-07-26. Estimated completion is 2024-04-02.
What conditions does trial NCT03519386 study?
This clinical trial studies the following conditions: Ocular Hypertension, Glaucoma Open-Angle.
What interventions are being tested in trial NCT03519386?
The interventions under investigation include: G2-TR intraocular implant containing travoprost (COMBINATION_PRODUCT), Sham surgery + active-comparator eye drops (DRUG).
Who is sponsoring clinical trial NCT03519386?
This trial is sponsored by Glaukos Corporation, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03519386 being conducted?
This trial has 1 study location across South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
RECRUITING · Phase 3
-
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
ACTIVE NOT RECRUITING · Phase 3
-
Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.